iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025
iCAD announced five clinical presentations and abstracts at the European Congress of Radiology (ECR) 2025, highlighting advancements in breast cancer detection, risk evaluation, and breast arterial calcification assessment. The presentations, scheduled from February 26 to March 2, 2025, in Vienna, will showcase research on AI-powered solutions for personalized risk assessment and early detection.
The company will present its new ProFound Cloud, a SaaS platform designed to deliver advanced AI solutions to healthcare providers globally. The presentations include studies on a 10-year image-derived AI risk model, optimal utilization of AI diagnostic software in mammography screening, short-term risk prediction comparisons, and workflow optimization in breast screening programs.
iCAD will demonstrate its latest innovations at booth AI-27, including the ProFound suite of solutions for DBT Detection, 2D Detection, Density Assessment, and Risk.
iCAD ha annunciato cinque presentazioni cliniche e abstract al Congresso Europeo di Radiologia (ECR) 2025, evidenziando i progressi nella rilevazione del cancro al seno, nella valutazione del rischio e nella valutazione della calcificazione arteriosa mammaria. Le presentazioni, programmate dal 26 febbraio al 2 marzo 2025 a Vienna, metteranno in mostra ricerche su soluzioni basate sull'IA per la valutazione personalizzata del rischio e la rilevazione precoce.
L'azienda presenterà il suo nuovo ProFound Cloud, una piattaforma SaaS progettata per fornire soluzioni avanzate di IA ai fornitori di assistenza sanitaria a livello globale. Le presentazioni includeranno studi su un modello di rischio basato su immagini derivato dall'IA di 10 anni, l'ottimale utilizzo di software diagnostici IA nello screening mammografico, confronti sulla previsione del rischio a breve termine e ottimizzazione del flusso di lavoro nei programmi di screening mammario.
iCAD dimostrerà le sue ultime innovazioni allo stand AI-27, inclusa la suite ProFound di soluzioni per la rilevazione DBT, la rilevazione 2D, la valutazione della densità e il rischio.
iCAD anunció cinco presentaciones clínicas y resúmenes en el Congreso Europeo de Radiología (ECR) 2025, destacando los avances en la detección del cáncer de mama, la evaluación de riesgos y la evaluación de la calcificación arterial mamaria. Las presentaciones, programadas del 26 de febrero al 2 de marzo de 2025 en Viena, mostrarán investigaciones sobre soluciones impulsadas por IA para la evaluación personalizada del riesgo y la detección temprana.
La empresa presentará su nueva ProFound Cloud, una plataforma SaaS diseñada para ofrecer soluciones avanzadas de IA a proveedores de salud en todo el mundo. Las presentaciones incluirán estudios sobre un modelo de riesgo derivado de imágenes de 10 años, la utilización óptima de software diagnóstico de IA en el cribado mamográfico, comparaciones de predicción de riesgo a corto plazo y optimización del flujo de trabajo en programas de cribado mamario.
iCAD demostrará sus últimas innovaciones en el stand AI-27, incluida la suite ProFound de soluciones para la detección DBT, detección 2D, evaluación de densidad y riesgo.
iCAD는 2025 유럽 방사선학회(ECR)에서 유방암 탐지, 위험 평가 및 유방 동맥 석회화 평가의 발전을 강조하는 다섯 가지 임상 발표 및 초록을 발표했습니다. 발표는 2025년 2월 26일부터 3월 2일까지 비엔나에서 예정되어 있으며, 맞춤형 위험 평가 및 조기 탐지를 위한 AI 기반 솔루션에 대한 연구를 선보일 것입니다.
회사는 전 세계 의료 제공자에게 고급 AI 솔루션을 제공하기 위해 설계된 새로운 ProFound Cloud라는 SaaS 플랫폼을 소개합니다. 발표에는 10년의 이미지 기반 AI 위험 모델, 유방 촬영 스크리닝에서 AI 진단 소프트웨어의 최적 활용, 단기 위험 예측 비교 및 유방 스크리닝 프로그램에서의 작업 흐름 최적화에 대한 연구가 포함됩니다.
iCAD는 AI-27 부스에서 DBT 탐지, 2D 탐지, 밀도 평가 및 위험을 위한 ProFound 솔루션 모음을 포함한 최신 혁신을 시연할 것입니다.
iCAD a annoncé cinq présentations cliniques et résumés au Congrès Européen de Radiologie (ECR) 2025, mettant en avant les avancées dans la détection du cancer du sein, l'évaluation des risques et l'évaluation de la calcification artérielle mammaire. Les présentations, prévues du 26 février au 2 mars 2025 à Vienne, présenteront des recherches sur des solutions alimentées par l'IA pour l'évaluation personnalisée des risques et la détection précoce.
L'entreprise présentera son nouveau ProFound Cloud, une plateforme SaaS conçue pour fournir des solutions avancées d'IA aux prestataires de soins de santé dans le monde entier. Les présentations incluront des études sur un modèle de risque dérivé d'images sur 10 ans, l'utilisation optimale des logiciels de diagnostic IA dans le dépistage mammographique, des comparaisons de prédictions de risque à court terme et l'optimisation des flux de travail dans les programmes de dépistage du sein.
iCAD démontrera ses dernières innovations au stand AI-27, y compris la suite de solutions ProFound pour la détection DBT, la détection 2D, l'évaluation de la densité et le risque.
iCAD hat fünf klinische Präsentationen und Abstracts beim Europäischen Kongress für Radiologie (ECR) 2025 angekündigt, in denen Fortschritte bei der Erkennung von Brustkrebs, der Risikobewertung und der Beurteilung der Brustarterienverkalkung hervorgehoben werden. Die Präsentationen, die vom 26. Februar bis 2. März 2025 in Wien stattfinden, werden Forschungen zu KI-gestützten Lösungen für die personalisierte Risikobewertung und die Früherkennung präsentieren.
Das Unternehmen wird seine neue ProFound Cloud vorstellen, eine SaaS-Plattform, die entwickelt wurde, um fortschrittliche KI-Lösungen weltweit an Gesundheitsdienstleister zu liefern. Zu den Präsentationen gehören Studien zu einem 10-jährigen, bildbasierten KI-Risikomodell, der optimalen Nutzung von KI-Diagnosesoftware beim Mammographie-Screening, Vergleichen zur kurzfristigen Risikovorhersage und der Optimierung von Arbeitsabläufen in Brustscreening-Programmen.
iCAD wird seine neuesten Innovationen am Stand AI-27 demonstrieren, einschließlich der ProFound-Lösungssuite für DBT-Erkennung, 2D-Erkennung, Dichtebewertung und Risiko.
- Launch of new ProFound Cloud platform expanding global healthcare provider access
- Five research presentations accepted at major industry conference (ECR 2025)
- Advancement in AI-powered breast health solutions portfolio
- None.
NASHUA, N.H., Feb. 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that five clinical presentations and abstracts highlighting the Company’s advancements in breast cancer detection, risk evaluation, and breast arterial calcification (BAC) assessment have been accepted for presentation at the European Congress of Radiology (ECR) 2025, which will take place from February 26 to March 2, 2025, in Vienna, Austria.
Led by research collaborators, these studies underscore iCAD’s commitment to delivering artificial intelligence (AI) powered solutions to advance personalized risk assessment, enhance early detection, and optimize breast imaging workflows.
“At iCAD, we are committed to pushing the boundaries of AI innovation in breast health, and the research being presented at ECR 2025 underscores the real-world impact and potential of our solutions,” said Dana Brown, President and CEO of iCAD. “These studies highlight how our solutions are advancing personalized risk evaluation, improving early detection, optimizing breast imaging workflows, and expanding the application of AI insights from a mammograph beyond breast health, ultimately supporting better outcomes for patients and providers worldwide. In line with this commitment, iCAD will present the new ProFound Cloud, a secure, scalable SaaS platform designed to deliver the company’s advanced AI solutions to healthcare providers worldwide.”
Presentation Details:
Oral Presentations:
- RPS 1002 – Exploring the Role of AI in Breast Imaging
February 27, 14:00 – 15:30 CET
Title: A 10-year image-derived AI risk model for use in primary prevention of breast cancer
Presenting Author: Mikael Eriksson, Stockholm, Sweden - RPS 705 – Artificial Intelligence in Breast Imaging
February 27, 08:00 – 09:30 CET
Title: Optimal utilization of an AI diagnostic software in a mammography screening program in Switzerland
Presenting Author: Marcel Blum, St. Gallen, Switzerland
- RPS 2202 – Personalized Risk Prediction of Breast Cancer
March 2, 08:00 – 09:00 CET- Title: Short-term risk prediction of breast cancer: Comparing risk tools for digital mammography and digital breast tomosynthesis in U.S. screening populations
Presenting Authors: Emily Conant, Chirag Parghi, Per Hall, and Mikael Eriksson - Title: Adding artificial intelligence (AI) case scoring in a breast screening program to optimize reading workflow and workload: A retrospective study
Presenting Author: Andrea Nitrosi, Reggio Emilia, Italy
- Title: Short-term risk prediction of breast cancer: Comparing risk tools for digital mammography and digital breast tomosynthesis in U.S. screening populations
EPOS Virtual Abstract Presentation:
- C-22811 (Virtual Poster)
Title: Rapid Prototyping of a Breast Arterial Calcification Detection Algorithm with Human-in-the-Loop Annotation
Authors: Yinhoa Ren, Jeff Hoffmeister, Jun Ge, Nikos Gkanatsios, Jonathan Go, Chirag Parghi, Emily Conant
iCAD will also showcase its latest AI-powered breast health innovations, including the ProFound Cloud which provides a fast, flexible and scalable access to iCAD’s ProFound full suite of solutions, including DBT Detection, 2D Detection, Density Assessment, and Risk. These presentations and live demonstrations at iCAD booth AI-27, Hall X-1 reinforce iCAD’s leadership in AI-driven breast health solutions, empowering radiologists with cutting-edge solutions to improve clinical outcomes, enhance workflow efficiency, and support personalized patient care.
For more information about iCAD’s participation at ECR 2025 or to schedule a demonstration, visit: www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/ecr-2025.
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
Media inquiries:
pr@icadmed.com
Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations icad@imsinvestorrelations.com
FAQ
What new product is ICAD launching at ECR 2025?
How many research presentations will ICAD showcase at ECR 2025?
When and where will ICAD present at ECR 2025?
What solutions are included in ICAD's ProFound suite?
